<DOC>
	<DOCNO>NCT00673582</DOCNO>
	<brief_summary>Rosuvastatin drug use low cholesterol , also cardiovascular benefit . The goal project determine rosuvastatin effective slowing development heart disease people HIV . We expect 2 year treatment people treat rosuvastatin show significantly well result people treat placebo .</brief_summary>
	<brief_title>Effectiveness Rosuvastatin Preventing Progression Atherosclerosis HIV Positive Patients</brief_title>
	<detailed_description>HIV+ patient least one cardiovascular risk factor randomize either rosuvastatin 10mg/day placebo period 96 week . B-mode carotid ultrasound ass primary outcome measure average total thickness ( composite measurement intima medium thickness total plaque area ) baseline , 24 , 48 , 72 96 week . We hypothesize rosuvastatin significantly effective respect inhibition change average total thickness baseline 96 week compare placebo .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>HIV positive , least one cardiovascular disease risk factor Diabetes Previous vascular disease Muscular disease Current use lipid lowering therapy</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Statins</keyword>
	<keyword>Intima Media Thickness</keyword>
	<keyword>Plaque Area</keyword>
</DOC>